Roivant Sciences has announced that it has entered into a licensing partnership with Poxel to develop and commercialise the latter’s experimental drug imeglimin for a range of metabolic disorders including type 2 diabetes, in a deal worth potentially over $600 million.
Roivant signs $600m licensing deal with Poxel
